Wolfgang Miesbach: When to Stop Anticoagulation after AF Ablation in 2026?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Karol Momot et al, published in Medical Science Monitor, adding:
”When to stop anticoagulation after AF ablation in 2026?
For the first time, two randomized trials – ALONE‑AF and OCEAN – directly address this clinical dilemma:
Guidelines
Current ESC and ACC/AHA guidelines still mandate at least 2–3 months of OAC after AF ablation in all patients and recommend that long‑term therapy be decided by CHA₂DS₂‑VA / CHA₂DS₂‑VASc rather than ‘successful ablation’ or sinus rhythm alone.
New randomized data
ALONE‑AF (JAMA 2025): In 840 low–intermediate risk patients ≥1 year post‑ablation without AF recurrence, stopping DOACs reduced major bleeding without increasing ischemic stroke over 2 years.
OCEAN (NEJM 2026): In 1,284 higher‑risk patients, rivaroxaban 15 mg vs aspirin showed no significant stroke advantage but more bleeding, questioning routine long‑term OAC after apparently stable ablation.
A large 2026 meta‑analysis (>270,000 patients) suggests no overall rise in thromboembolism or mortality when OAC is stopped, but CHA₂DS₂‑VASc >2 is a red flag (higher thromboembolic risk if you discontinue).
Timing matters
All randomized data so far assume OAC is continued for ≥12 months after ablation before considering withdrawal;the optimal earlier time point (for example 6 months) remains unknown and is hypothesis‑generating only.
Practical 2026 message
In selected, well‑monitored patients, OAC withdrawal ≥1 year after ‘successful’ AF ablation is now evidence‑supported, but high‑risk patients should still stay on lifelong anticoagulation.
Congratulations to Karol Momot, LukaszSzarpak and co-authors on this excellent review.”
Title: Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation – Are We Ready to Change Clinical Practice in 2026?
Authors: Karol Momot, Stanisław Surma, Kamil Krauz, Michał Pruc, Łukasz Szarpak, Dariusz Rodkiewicz, Małgorzata Buksińska-Lisik, Artur Mamcarz
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 18, 2026, 06:27Gregory Makris: NEJM Study Supports Earlier Catheter-Directed Intervention in Intermediate-High–Risk PE
-
Oct 18, 2026, 06:26Danny Hsu: BLOOD 2026 Return to Aotearoa
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH
-
Oct 18, 2026, 01:44Marta Velia Antonini: How to Deliver CRRT during ECMO?
-
Oct 18, 2026, 01:19Aamir Saeed: Anticoagulation, Cirrhosis, and Other Risk Factors for Post-ERCP Bleeding
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke